Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor Will Support Xopenex HFA Launch With Three Sales Forces

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm will use two primary care sales forces and one specialty respiratory sales force to detail the hydrofluoroalkane metered-dose inhaler.

You may also be interested in...



Sepracor Seeks FDA Nod For Long-Acting Beta Agonist Arformoterol

User fee date for the chronic obstructive pulmonary disease agent would fall in October, assuming a standard 10-month review.

CFC-Containing Albuterol Inhalers To Be Removed By 2009

FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.

Future BIO Global Efforts Include International Relations, Greenwood Says

HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel